Hunter Shkolnik Comments on Proposed Opioid Settlement

December 5, 2019

Source: Daily Stock Dish

Teva Pharmaceutical Industries Ltd.'s proposed $23 billion drug giveaway to settle thousands of U.S. opioid lawsuits will likely cost the company a fraction of that figure due to how it has valued those medicines, according to a Reuters review of pricing data and industry analysts. The deal is "overvalued to make the settlement look better," said Hunter Shkolnik, a lawyer on the plaintiffs executive committee that is managing more than 2,300 federal lawsuits consolidated in the U.S. District Court in Cleveland. "I don't believe a no-cash payment from Teva, one of the largest generic manufacturers in the world, is appropriate," he told Reuters. Israel-based Teva is looking to reach a nationwide settlement over its role in selling opioid painkillers, together with drugmaker Johnson & Johnson and the three largest U.S. drug distributors, AmerisourceBergen Corp, Cardinal Health Inc and McKesson Corp.
Download

Featured Attorneys

Partner and Attorney Hunter J. Shkolnik

More Publications

Daily Stock Dish

Our Locations

Please Contact Us for an In-Person Appointment